Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
21actual
Sites
25
Countries
Australia, Canada, Turkey (Türkiye) +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-06-22 | actual | When the study began enrolling |
| Primary completion | 2026-07-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-23 | actual | The whole study's end, after follow-up |
| First posted | 2017-10-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hemophilia B
Intervention
- Biological: PF-06838435 (formerly SPK-9001)
Primary outcome
what the primary-completion date above is the date OFIncidence of PF-06838435 related adverse events
measured Baseline up to Year 6
Publications
- PMID 41734390 — linked by the registry
- PMID 40750723 — linked by the registry
- PMID 40239068 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed